GM-3009

GM-3009 is a highly potent, orally bioavailable small molecule analogue of noribogaine and ibogaine under development by Gilgamesh Pharmaceuticals for the treatment of opioid use disorder (OUD), post-traumatic stress disorder (PTSD), and traumatic brain injury (TBI)[1][6][7][8]. It acts primarily as a κ-opioid receptor agonist with high affinity for the human KOR[1]. Preclinical studies show that GM-3009 produces antinociceptive effects and reduces oxycodone self-administration in rodents[1]. Unlike traditional ibogaine, which is limited by significant cardiovascular toxicity, GM-3009 has been engineered to eliminate pro-arrhythmic effects while retaining or improving therapeutic efficacy[6][8]. As of June 2024, it remains in preclinical development with IND-enabling studies underway supported by a grant from the US National Institute on Drug Abuse[5][6].

Other names

oxa-noribogaine